A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, October 20, 2014
Experimental Spasticity Drug Being Tested, Will Enter Multiple Sclerosis Trials in Early 2015
Concert Pharmaceuticals, Inc. will announce their latest results from the Phase 1 data of CTP-354, a drug developed to treat spasticity — a chronic condition associated with patients with brain disorders, including Multiple Sclerosis – at the next American Neurological Association’s Annual Meeting in Baltimore, Maryland.
The Phase 1 randomized, double-blind, placebo-controlled trial, was performed in 30 healthy individuals with the primary endpoint to evaluate the drug’s safety and tolerability with three different dosages — 2 mg, 6 mg. and 12 mg — to be administered over the course of 10 days.
The results to be presented will show CTP-354 was well tolerated, with a plasma half-life of 20 hours observed in all tested doses and without interference in both fasted and fed states.
According to these latest results and together with results obtained from a previous phase trial (that determined support for CTP-354 once a day dose and a sustained occupancy of GABBA receptors in the brain), Concert Pharmaceuticals announced a Phase 2 trial will be initiated by the end of this year. The Phase 2 trial will focus on the effects of CTP-354 in spasticity associated with spinal cord injury and spasticity associated with multiple sclerosis.